BOLDON-U – Boldenone Undecylenate 300mg/ml 5x2ml Box

PHARMACEUTICAL NAME: Boldenone Undecylenate

MOLECULAR STRUCTURE: C30H44O3

PROPRIETARY NAME: BOLDON-U

DOSAGE FORM: 300 mg/ml injection

COMPOSITION: Each ml of BOLDON-U contains Boldenone Undecylenate in oil base q.s.

PHARMACOLOGICAL CLASSIFICATION: Anabolic Steroids

DESCRIPTION:

BOLDON-U is having both androgenic and anabolic properties when administered parentally. It has the Undecylenate ester attached to it which allows for slower release into the blood stream. It was first created with the intention of being used on animals such has horses. BOLDON-U is derived from Testosterone and has the same Anabolic properties and Testosterone but much lower Androgenic properties and therefore the side effects related to BOLDON-U are rather low.

CONTRAINDICATIONS:

Contraindicated in infant, pregnancy & lactating mothers. Carcinoma of prostate and carcinoma of male breast. It is not intended for use in female patients other than those with disseminated breast cancer. Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE:

BOLDON-U injections should be administered intramusculary, preferably deep into the gluteal muscle.

Adults:

Effective Dose Males – Intramuscular, 300 – 600 mg/week (2 mg/lb of Body weight)

Effective Dose Females – Intramuscular, 100 to 200 mg/week

Active life: 9 days

SIDE EFFECTS:

Oedema, cholestatic jaundice, hepatic carcinoma. Gynaecomastia. Precocious puberty & shortening of stature due to early closure of epiphysis. Rashes, cramps, dyspepsia. Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased libido and menstrual irregularities.

PRECAUTIONS:

Patients with the following conditions should be monitored:

1) In cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention.

2) Diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs.

3) Incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure.

4) Skeletal metastases, since anabolic steroids may induce hypercalcemia and hypercalciuria in these patients.

5) Liver dysfunction.

6) If signs of virilization develops, treatment should be discontinued.

DRUG INTERACTIONS:

Potentiates corticosteroids. Potentiates oral anticoagulants, thereby enhancing bleeding tendency. Liver-enzyme-inducing agents may reduce the effects of BOLDON-U by enhancing its metabolism in the liver.

OVERDOSAGE:

It is not frequent because physician or other expert administers it. Acute intramuscular toxicity of BOLDON-U is very low.

STORAGE CONDITIONS:

Store in a cool dry place below 25 °C.

Not to be refrigerated.

Protect from light.

Keep out of reach of children.

PACKAGING:

BOX: 5 vials of 2 ml (300 mg/ml)

MARKETED BY:

Pharmed Corporation Ltd., 3361/A, Rani Bagh, Mahindra Park Rajdhani Enclave, Shakurpur, New Delhi, Delhi 110034, India tel +919953242466, http://www.pharmed-corp.com

DATE OF PUBLICATION OF THIS PACKAGE INSERT:

04.2020